LGND FY 2021 Earnings — Ligand Pharmaceuticals Incorporated Revenue & Financial Results | Market Cap Arena

LGNDLigand Pharmaceuticals Incorporated

$4B

FY 2021 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$242M+47.7% YoY

Gross Profit

$179M74.3% margin

Operating Income

$104M43.0% margin

Net Income

$57M23.7% margin

EPS (Diluted)

$3.34

Cash Flow

Operating Cash Flow

$79M

Free Cash Flow

$70M

Stock-Based Comp.

$39M

Balance Sheet

Total Assets

$1.3B

Total Liabilities

$476M

Stockholders' Equity

$821M

Cash & Equivalents

$20M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$242M	$164M	+47.7%
Gross Profit	$179M	$133M	+34.7%
Operating Income	$104M	$38M	+176.9%
Net Income	$57M	-$3M	+2014.2%